Lipoprotein subclasses are associated with Hepatic steatosis: insights from the prospective multicenter imaging study for the evaluation of chest pain (PROMISE) clinical trial

Julia Karady; Robert W McGarrah; Maggie Nguyen; Stephanie N Giamberardino; Nandini Meyersohn; Michael T Lu; Pedro V Staziaki; Stefan B Puchner; Daniel O Bittner; Borek Foldyna; Thomas Mayrhofer; Margery A Connelly; Andre Tchernof; Phillip J White; Khurram Nasir; Kathleen Corey; Deepak Voora; Neha Pagidipati; Geoffrey S Ginsburg; William E Kraus; Udo Hoffmann; Pamela S Douglas; Svati H Shah; Maros Ferencik

American Journal of Preventive Cardiology (Jun 2024)

Lipoprotein subclasses are associated with Hepatic steatosis: insights from the prospective multicenter imaging study for the evaluation of chest pain (PROMISE) clinical trial

Julia Karady,
Robert W McGarrah,
Maggie Nguyen,
Stephanie N Giamberardino,
Nandini Meyersohn,
Michael T Lu,
Pedro V Staziaki,
Stefan B Puchner,
Daniel O Bittner,
Borek Foldyna,
Thomas Mayrhofer,
Margery A Connelly,
Andre Tchernof,
Phillip J White,
Khurram Nasir,
Kathleen Corey,
Deepak Voora,
Neha Pagidipati,
Geoffrey S Ginsburg,
William E Kraus,
Udo Hoffmann,
Pamela S Douglas,
Svati H Shah,
Maros Ferencik

Affiliations

Julia Karady: Cardiovascular Imaging Research Center, Harvard Medical School - Massachusetts General Hospital, MA, USA; MTA-SE Cardiovascular Imaging Research Group, Heart and Vascular Center, Semmelweis University, Budapest, Hungary
Robert W McGarrah: Duke Molecular Physiology Institute, Duke University, Durham, NC, USA
Maggie Nguyen: Duke Molecular Physiology Institute, Duke University, Durham, NC, USA
Stephanie N Giamberardino: Duke Molecular Physiology Institute, Duke University, Durham, NC, USA
Nandini Meyersohn: Cardiovascular Imaging Research Center, Harvard Medical School - Massachusetts General Hospital, MA, USA
Michael T Lu: Cardiovascular Imaging Research Center, Harvard Medical School - Massachusetts General Hospital, MA, USA
Pedro V Staziaki: Cardiovascular Imaging Research Center, Harvard Medical School - Massachusetts General Hospital, MA, USA; University of Vermont Medical Center, Robert Larner College of Medicine at the University of Vermont, Burlington, VT, USA
Stefan B Puchner: Cardiovascular Imaging Research Center, Harvard Medical School - Massachusetts General Hospital, MA, USA; Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria
Daniel O Bittner: Cardiovascular Imaging Research Center, Harvard Medical School - Massachusetts General Hospital, MA, USA; Friedrich-Alexander University Erlangen-Nürnberg, Department of Cardiology, University Hospital Erlangen, Germany
Borek Foldyna: Cardiovascular Imaging Research Center, Harvard Medical School - Massachusetts General Hospital, MA, USA
Thomas Mayrhofer: Cardiovascular Imaging Research Center, Harvard Medical School - Massachusetts General Hospital, MA, USA; School of Business Studies, Stralsund University of Applied Sciences, Stralsund, Germany
Margery A Connelly: Labcorp Inc., Morrisville, NC, USA
Andre Tchernof: Quebec Heart and Lung Institute, School of Nutrition, Laval University, Canada; Institute of Nutrition and Functional Foods, Laval University, Canada
Phillip J White: Duke Molecular Physiology Institute, Duke University, Durham, NC, USA; Department of Medicine, Division of Endocrinology, Metabolism and Nutrition, Duke University, Durham, NC, USA; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA
Khurram Nasir: Division of Cardiovascular Prevention and Wellness, Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Houston, TX, USA
Kathleen Corey: Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Deepak Voora: Duke Precision Medicine Program, Duke University School of Medicine, Durham, NC, USA
Neha Pagidipati: Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA
Geoffrey S Ginsburg: All of Us Research Program, National Institutes of Health, MD Innovative Imaging, Bethesda, USA
William E Kraus: Duke Molecular Physiology Institute, Duke University, Durham, NC, USA
Udo Hoffmann: Cardiovascular Imaging Research Center, Harvard Medical School - Massachusetts General Hospital, MA, USA; Consulting LLC, Waltham, MA, USA; Cleerly Inc., Denver, CO, USA
Pamela S Douglas: Duke Molecular Physiology Institute, Duke University, Durham, NC, USA
Svati H Shah: Duke Molecular Physiology Institute, Duke University, Durham, NC, USA
Maros Ferencik: Knight Cardiovascular Institute, Oregon Health and Science University, Portland, OR, USA; Corresponding author at: Postal address: 3181 SW Sam Jackson Park Road Portland, OR 97239, USA

Journal volume & issue: Vol. 18
p. 100680

Abstract

Read online

Objectives: To determine the relationship between lipoprotein particle size/number with hepatic steatosis (HS), given its association with traditional lipoproteins and coronary atherosclerosis. Methods: Individuals with available CT data and blood samples enrolled in the PROMISE trial were studied. HS was defined based on CT attenuation. Lipoprotein particle size/number were measured by nuclear magnetic resonance spectroscopy. Principal components analysis (PCA) was used for dimensionality reduction. The association of PCA factors and individual lipoprotein particle size/number with HS were assessed in multivariable regression models. Associations were validated in an independent cohort of 59 individuals with histopathology defined HS. Results: Individuals with HS (n=410/1,509) vs those without (n=1,099/1,509), were younger (59±8 vs 61±8 years) and less often females (47.6 % vs 55.9 %). All PCA factors were associated with HS: factor 1 (OR:1.36, 95 %CI:1.21–1.53), factor 3 (OR:1.75, 95 %CI:1.53–2.02) and factor 4 (OR:1.49; 95 %CI:1.32–1.68) were weighted heavily with small low density lipoprotein (LDL) and triglyceride-rich (TRL) particles, while factor 2 (OR:0.86, 95 %CI:0.77–0.97) and factor 5 (OR:0.74, 95 %CI:0.65–0.84) were heavily loaded with high density lipoprotein (HDL) and larger LDL particles. These observations were confirmed with the analysis of individual lipoprotein particles in PROMISE. In the validation cohort, association between HS and large TRL (OR: 8.16, 95 %CI:1.82–61.98), and mean sizes of TRL- (OR: 2.82, 95 %CI:1.14–9.29) and HDL (OR:0.35, 95 %CI:0.13–0.72) were confirmed. Conclusions: Large TRL, mean sizes of TRL-, and HDL were associated with radiographic and histopathologic HS. The use of lipoprotein particle size/number could improve cardiovascular risk assessment in HS.

Published in American Journal of Preventive Cardiology

ISSN: 2666-6677 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the circulatory (Cardiovascular) system; Medicine: Public aspects of medicine
Website: https://www.journals.elsevier.com/american-journal-of-preventive-cardiology/

About the journal

Abstract

Keywords